CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer

被引：0

作者：

Matsubara, N. ^{[1
]}

Agarwal, N. ^{[2
]}

Smith, M. R. ^{[3
]}

Mckay, R. R. ^{[4
]}

Todenhofer, T. ^{[5
]}

Piulats Rodriguez, J. M. ^{[6
]}

Chung, K. L. ^{[7
]}

Heirich, D. ^{[8
]}

Sherwood, S. ^{[9
]}

Schaverien, C. ^{[10
]}

Fasnacht, N. ^{[11
]}

Lithio, A. ^{[12
]}

Nacerddine, K. ^{[13
]}

Zhang, T. ^{[14
]}

机构：

[1] Natl Canc Ctr Hosp East, Med Oncol, Kashiwa, Chiba, Japan

[2] Univ Utah Hlth, Huntsman Canc Inst, Oncol Internal Med Dept, Salt Lake City, UT USA

[3] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Oncol, Boston, MA USA

[4] Univ Calif San Diego UCSD, Med, La Jolla, CA USA

[5] Studienpraxis Urol, Clin Trial Unit, Nuertingen, Germany

[6] Hosp Duran & Reynals, ICO Inst Catala Oncol Hosp, Dept Med Oncol, Barcelona, Spain

[7] Eli Lilly & Co, Oncol, New York, NY USA

[8] Loxo Oncol Inc, Clin Sci, South San Francisco, CA USA

[9] Eli Lilly & Co, Med, West Ryde, NSW, Australia

[10] Eli Lilly & Co, Oncol, Indianapolis, IN USA

[11] Eli Lilly Suisse SA, Oncol Dept, Vernie, Switzerland

[12] Eli Lilly & Co, Stat Dept, Indianapolis, IN USA

[13] Eli Lilly France, Global Clin Dev, Neuilly sur Seine, France

[14] UT Southwestern Med Ctr, Simmons Comprehens Canc Ctr, Internal Med Dept, Dallas, TX USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.791

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

284TiP

引用

页码：S1582 / S1583

页数：2

共 50 条

[1] CYCLONE 3: A Phase 3, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer (mHSPC)
Piulats, J. M.
Smith, M.
Matsubara, N.
Zhang, T.
Agarwal, N.
Mckay, R. R.
Johnston, E.
Sherwood, S.
Schaverien, C.
Fasnacht, N.
Lithio, A.
Nacerddine, K.
Todenhoefer, T.
EUROPEAN UROLOGY, 2023, 83 : S757 - S757
[2] CYCLONE 3: A phase 3, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk, metastatic, hormone-sensitive prostate cancer (mHSPC).
Smith, Matthew Raymond
Matsubara, Nobuaki
Mckay, Rana R.
Piulats, Josep M.
Todenhofer, Tilman
Zhang, Tian
Fasnacht, Nicolas
Sherwood, Sarah
Johnston, Erica L.
Schaverien, Clare
Lithio, Andrew
Nacerddine, Karim
Agarwal, Neeraj
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[3] CYCLONE 3: A phase III, randomized, double-blind, placebocontrolled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer (mHSPC)
Mckay, R. R.
Agarwal, N.
Matsubara, N.
Rodriguez, J. M. Piulats
Smith, M. R.
Todenhofer, T.
Zhang, T.
Balar, A. V.
Schaverien, C.
Sherwood, S.
Johnston, E.
Lithio, A.
Nacerddine, K.
Sweeney, C. J.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1195 - S1196
[4] A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (MAGNITUDE).
Chi, Kim N.
Rathkopf, Dana E.
Attard, Gerhardt
Smith, Matthew Raymond
Efstathiou, Eleni
Olmos, David
Small, Eric Jay
Lee, Ji Youl
Ricci, Deborah S.
Simon, Jason S.
Zhao, Xin
Kothari, Nishi
Cheng, Shinta
Sandhu, Shahneen Kaur
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[5] A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)
Chi, K. N.
Rathkopf, D.
Attard, G.
Smith, M. R.
Efstathiou, E.
Olmos, D.
Small, E. J.
Lee, J. Y.
Sieber, P.
Dunshee, C.
Ricci, D.
Simon, J. S.
Zhao, X.
Kothari, N.
Cheng, S.
Sandhu, S. K.
ANNALS OF ONCOLOGY, 2019, 30
[6] A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)
Chi, Kim N.
Rathkopf, Dana E.
Attard, Gerhardt
Smith, Matthew Raymond
Efstathiou, Eleni
Olmos, David
Small, Eric Jay
Lee, Ji Youl
Sieber, Paul R.
Dunshee, Curtis
Ricci, Deborah S.
Simon, Jason S.
Zhao, Xin
Kothari, Nishi
Cheng, Shinta
Sandhu, Shahneen Kaur
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[7] Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study
Saad, Fred
Efstathiou, Eleni
Attard, Gerhardt
Flaig, Thomas W.
Franke, Fabio
Goodman, Oscar B., Jr.
Oudard, Stephane
Steuber, Thomas
Suzuki, Hiroyoshi
Wu, Daphne
Yeruva, Kesav
De Porre, Peter
Brookman-May, Sabine
Li, Susan
Li, Jinhui
Thomas, Shibu
Bevans, Katherine B.
Mundle, Suneel D.
McCarthy, Sharon A.
Rathkopf, Dana E.
LANCET ONCOLOGY, 2021, 22 (11): : 1541 - 1559
[8] Abiraterone plus prednisone in patients with newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC)
Miller, Kurt
AKTUELLE UROLOGIE, 2019, 50 (06) : 625 - 628
[9] CYCLONE 2: A phase 2/3, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer.
Smith, Matthew Raymond
Agarwal, Neeraj
Todenhofer, Tilman
Piulats, Josep M.
Lee, Jae-Lyun
Trepiakas, Redas
Rao, Arpit
Horvath, Lisa
Lithio, Andrew
Johnston, Erica L.
Hulstijn, Maarten
Nacerddine, Karim
Sweeney, Christopher
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[10] Final Overall Survival Analysis From ARCHES: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Enzalutamide Plus Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (11) : 17 - 18

← 1 2 3 4 5 →